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Abstract 1 
Background: Epidemiological studies have supported inverse associations between low 2 
serum 25-hydroxyvitamin D [25(OH)D] and cardiometabolic risk markers, but few 3 
randomized trials have investigated the effect of vitamin D supplementation on these markers 4 
in adolescents. 5 
Objective: The objective of this study was to investigate the effect of winter-time 6 
cholecalciferol (vitamin D3) supplementation on cardiometabolic risk markers in white, 7 
healthy 14-18 year-old adolescents in the UK (51°N) as part of the ODIN Project. 8 
Methods: In a dose-response trial, 110 adolescents (15.9±1.4 years; 43% male; 81% normal 9 
weight) were randomly assigned to receive 0, 10 or 20 μg/day vitamin D3 for 20 weeks 10 
(October-March). Cardiometabolic risk markers including BMI-for-age z-score (BMIz), waist 11 
circumference, systolic and diastolic blood pressure, fasting plasma triglycerides, cholesterol 12 
(total, HDL, LDL and total:HDL) and glucose were measured at baseline and endpoint as 13 
secondary outcomes, together with serum 25(OH)D. Intervention effects were evaluated in 14 
linear regression models as between-group differences at endpoint, adjusted for the baseline 15 
value of the outcome variable and additionally for age, sex, Tanner stage, BMIz and baseline 16 
serum 25(OH)D. 17 
Results: Mean±SD baseline serum 25(OH)D was 49.1±12.3 nmol/L and differed between 18 
groups at endpoint with concentrations of 30.7±8.6, 56.6±12.4 and 63.9±10.6 nmol/L in the 0, 19 
10 and 20 μg/day groups respectively (P≤0.001). Vitamin D3 supplementation had no effect 20 
on any of the cardiometabolic risk markers (all P>0.05), except for lower HDL (-0.12 21 
mmol/L, 95% CI -0.21, 0.04, P=0.003) and total cholesterol (-0.21 mmol/L, 95% CI -0.42, 22 
0.00, P=0.05) in the 20 compared to the 10 μg/day group, which disappeared in the fully 23 
adjusted analysis (P=0.27 and P=0.30 respectively).  24 
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Conclusions: Supplementation with vitamin D3 at 10 and 20 μg/day, which increased serum 25 
25(OH)D concentrations during the winter-time, had no effect on markers of cardiometabolic 26 
risk in healthy 14-18 year-old adolescents. This trial was registered at clinicaltrials.gov as 27 
NCT02150122. 28 
 29 
Keywords: vitamin D, adolescents, cardiovascular risk factors, randomized controlled trial 30 
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Introduction 31 
Despite significant improvements in treatments and survival rates, cardiovascular disease 32 
(CVD) remains an important cause of mortality and morbidity in the UK (1) and globally (2), 33 
with the economic and social burden only expected to increase with an aging population (3). 34 
Whilst some of the risk factors for CVD, such as age, sex and ethnicity, are non-modifiable, 35 
others, particularly physiological/biochemical factors such as abdominal obesity, 36 
hypertension, abnormal blood lipids, diabetes, and lifestyle factors including physical 37 
inactivity and poor dietary patterns, are prevalent and potentially modifiable, making these 38 
key targets for CVD prevention.  39 
 40 
A role for vitamin D in CVD was postulated over 30 years ago with the recognition of 41 
seasonality in CVD mortality, attributed to variations in ultra-violet radiation (4). 42 
Experimental studies have demonstrated mechanistic roles for vitamin D in reduced 43 
triglycerides and cholesterol secretion and increased peripheral removal (5, 6), pancreatic β-44 
cell function (7) and in the endocrine regulation of blood pressure through the renin-45 
angiotensin system (8). However, whilst the synthesis of epidemiological (9) and prospective 46 
data (10, 11) in adult populations appear to support this association between low circulating 47 
25-hydroxyvitamin D [25(OH)D; biomarker of vitamin D status] and markers of 48 
cardiometabolic risk and cardiac events, intervention data remains limited and inconclusive 49 
(12, 13). 50 
 51 
With strong evidence that CVD risk factors track individually (14, 15) and potentially as a 52 
combined risk phenotype (16) from childhood to adulthood, early prediction and prevention 53 
may be key to reducing the global burden of CVD. In both high and low-middle income 54 
countries adolescent populations have been shown to express a number of recognised 55 
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physiological and behavioural CVD risk factors (17, 18). Furthermore, adolescents are a 56 
population group with a recognised risk of low vitamin D status (19, 20) and with data 57 
suggesting particularly strong tracking of CVD risk factors from adolescence to adulthood 58 
(21), adolescents may be a key target population for early prevention.  59 
 60 
However, no consistent associations have been identified between circulating 25(OH)D and 61 
markers of cardiometabolic risk in adolescents (22). Limited randomized controlled trials 62 
have found daily vitamin D supplementation at 50-100 μg to reduce arterial stiffness, but not 63 
blood pressure, in normal weight adolescents (23), and improve insulin resistance in obese 64 
adolescents (24), but with no effect on fasting glucose, triglycerides or total, low-density 65 
lipoprotein (LDL) or high-density lipoprotein (HDL) cholesterol concentrations in other trials 66 
(25-27). However many of the previous trials have been conducted in small samples (n < 60) 67 
of largely obese adolescents at latitudes of < 45°N during times when skin exposure to 68 
sunlight will influence vitamin D status.  69 
 70 
In a dose-response, randomized controlled trial among white, healthy 14-18 year-old 71 
adolescents residing in the UK (51°N), we have previously shown that cholecalciferol 72 
(vitamin D3) supplementation at 10 and 20 µg/day during the winter-time increased serum 73 
25(OH)D concentrations and prevented the seasonal decline seen in the placebo group (28). 74 
The aim of the present study was to investigate the effect of vitamin D3 supplementation on 75 
cardiometabolic risk markers (BMI-for-age z-score, waist circumference, blood pressure, 76 
plasma lipids and glucose) as a secondary analysis of the randomized controlled trial. 77 
Baseline associations between serum 25(OH)D and markers of cardiometabolic risk were also 78 
determined. 79 
 80 
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Methods 81 
Study design and participants 82 
The present study is a secondary analysis of a vitamin D dose-response, placebo-controlled 83 
randomized trial that was conducted within the pan-European ODIN Project (Food based 84 
Solutions for Optimal vitamin D Nutrition and health through the life cycle). The primary aim 85 
of the study was to estimate dietary requirements for vitamin D in adolescents as previously 86 
reported (28). The study was conducted in parallel with a similarly designed trial in 4-8 year-87 
old Danish children with the same primary aim (29) and secondary analyses as reported by 88 
Hauger et al. in the current issue of the journal (30). In brief, 110 healthy, white male and 89 
female adolescents aged 14-18 years, not currently taking vitamin D containing supplements 90 
or planning a winter sun vacation, were recruited onto the study and randomly allocated to 91 
receive a daily supplement of either 0, 10 or 20 μg vitamin D3 for 20 weeks during the winter-92 
time (October – March) (Figure 1).  93 
 94 
The study was approved by the National Research Ethics Service Committee West Midlands 95 
(NHS REC reference 14/WM/0090) and the University of Surrey Ethics Committee 96 
(EC/2014/83/FHMS Fast Track). The trial was registered at clinicaltrials.gov as 97 
NCT02150122. The study was conducted in accordance with the Helsinki Declaration. 98 
Written informed consent was obtained from all participants, along with consent from their 99 
parent/guardian if the subject was < 16 years of age. 100 
 101 
Data collection 102 
Participants visited the University of Surrey (Guildford, UK; 51°N) on two occasions at the 103 
beginning (October 2014) and end of the trial (March 2015). At each visit, an overnight fasted 104 
blood sample was obtained by venipuncture by a trained phlebotomist between 0700 and 105 
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1100. Participants’ standing height, weight and waist circumference were measured by 106 
standardized procedures as previously described (28). BMI-for-age z-score (BMIz) and BMI-107 
for-age percentiles were calculated using the WHO AnthroPlus software (31). Blood pressure 108 
of the non-dominant arm was measured using an automatic blood pressure monitor (Omron 109 
Healthcare Ltd, Kyoto, Japan) while participants were sat in an up-right position with the arm 110 
supported. Readings were repeated three times, one minute apart and an average reading was 111 
calculated. Participants’ Tanner stage was determined using a self-administered questionnaire 112 
based on the five stages of pubertal development (32). Habitual dietary vitamin D and 113 
calcium intakes were estimated using an interviewer-administered validated food frequency 114 
questionnaire (33). Physical activity was assessed using a self-administered questionnaire 115 
including items on frequency, duration and type of activity both inside and outside of school. 116 
Compliance was assessed by regular telephone interviews and by tablet count of returned 117 
supplements at the end of the trial. 118 
 119 
Laboratory analysis 120 
All samples were stored at -80°C prior to analysis. Serum 25(OH)D concentrations were 121 
measured by liquid chromatography-tandem mass spectrometry as previously described (28). 122 
The intra- and interassay CVs were < 5% and < 6% respectively. Fasting plasma triglycerides, 123 
total and HDL cholesterol and glucose concentrations were measured using an enzymatic 124 
automated colorimetric method (ILAB 650, Instrumentation Laboratory, Milan, Italy) at the 125 
University of Surrey. All samples were measured in duplicate and a mean value was 126 
calculated. QCs were measured in triplicate at the beginning and end of each run. The intra- 127 
and interassay CVs were < 2.5% and < 1.5% respectively. LDL cholesterol concentrations 128 
were calculated using the following formula: LDL cholesterol = total cholesterol – HDL 129 
cholesterol – (triglycerides/5) (34). 130 
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 131 
Statistical analysis 132 
Descriptive statistics were determined for all variables and reported as mean ± SD or median 133 
(IQR) for continuous variables and frequency (%) for categorical variables. Presented values 134 
are mean ± SD unless otherwise stated. Unadjusted and adjusted linear regression analyses 135 
were conducted to investigate the associations between baseline serum 25(OH)D 136 
concentration and markers of cardiometabolic risk. Multivariate models were constructed to 137 
include adjustment for sex, age, Tanner stage, BMIz and physical activity levels. The effect of 138 
vitamin D3 supplementation was evaluated as between-group differences in the endpoint 139 
cardiometabolic risk markers, adjusted for the baseline value of the outcome variable in linear 140 
regression analyses. Additional analyses were adjusted for sex, age, Tanner stage, BMIz and 141 
baseline serum 25(OH)D concentration due to its influence on serum 25(OH)D response to 142 
vitamin D3 supplementation (28). To further verify the results, dose-response associations 143 
between changes from baseline to endpoint in serum 25(OH)D and the cardiometabolic risk 144 
markers were made with similar adjustments as described above. Model assumptions were 145 
checked by visual inspection of residual and normal probability plots. Waist circumference 146 
and plasma triglycerides were log transformed before analysis and presented estimates back 147 
transformed. To allow for explorative findings in this secondary analysis, adjustment for 148 
multiple comparisons were not made. Statistical analysis of the data was completed using 149 
SPSS for Windows (version 22.0; IBM Corporation, Armonk, NY). A P value of < 0.05 was 150 
considered significant. 151 
 152 
The original power calculation for the randomized controlled trial was based on the slope of 153 
the relationship between total vitamin D intake and endpoint serum 25(OH)D concentration 154 
(28). For the cardiometabolic outcomes, differences of at least 0.71 standard deviations 155 
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between any of the intervention groups could be detected with a power of 0.8 and significance 156 
level of 0.05. This corresponds to differences of 5.9 mmHg in diastolic blood pressure and 157 
0.41 mmol/L in LDL cholesterol. 158 
 159 
Results 160 
Compliance and protocol adherence 161 
Of the 110 participants recruited onto the study, a total of 105 participants completed the 162 
intervention and 102 were included in the analysis. Five participants dropped out of the study 163 
(4.5%); n = 2 participants were excluded from the per protocol analysis due to 164 
commencement of fish-oil supplementation, which contained vitamin D, halfway through the 165 
intervention period and; n = 1 participant was excluded from the analysis due to an endpoint 166 
serum 25(OH)D concentration > 125 nmol/L, which was deemed an outlier when the 167 
distribution of the data was inspected (Figure 1). Median (IQR) compliance was 99% 168 
(95,100).  169 
 170 
Baseline characteristics of study participants 171 
The baseline characteristics of the study participants are shown in Table 1. Adolescents were 172 
15.9 ± 1.4 years of age, 43% were male and BMIz was 0.10 ± 1.01. Eighty-one percent were 173 
of a normal weight, 12% were overweight and 7% were obese. Serum 25(OH)D was 49.1 ± 174 
12.3 nmol/L; 5% of adolescents had 25(OH)D concentrations < 30 nmol/L and 45% had 175 
concentrations > 50 nmol/L. 176 
 177 
Baseline associations between serum 25(OH)D and cardiometabolic risk markers 178 
Baseline serum 25(OH)D was inversely associated with BMIz (β = -0.44, P < 0.001) and 179 
waist circumference (β = -0.04, P = 0.002) after adjusting for sex, age, Tanner stage and 180 
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physical activity. An inverse association was also seen for serum 25(OH)D and triglycerides 181 
in the unadjusted analysis (β = -0.01, P = 0.008), but not after adjustment (P > 0.05). There 182 
were no other associations between serum 25(OH)D concentrations and cardiometabolic risk 183 
markers (all P > 0.05) (Table 2). 184 
 185 
Effect of vitamin D3 supplementation on serum 25(OH)D and cardiometabolic risk markers 186 
From baseline, serum 25(OH)D concentrations increased to 56.6 ± 12.4 nmol/L and 63.9 ± 187 
10.6 nmol/L in the 10 and 20 μg/day groups respectively, and decreased to 30.7 ± 8.6 nmol/L 188 
in the placebo group (all P ≤ 0.001) as previously reported (28).  189 
 190 
Daily vitamin D3 supplementation at 10 or 20 μg/day for 20 weeks had no effect on BMIz, 191 
waist circumference, systolic and diastolic blood pressure, plasma triglycerides, total, LDL 192 
and total:HDL cholesterol and glucose (Table 3). However, those in the 20 μg/day 193 
intervention group had lower plasma HDL cholesterol of -0.12 mmol/L (95% CI -0.21, 0.04, 194 
P = 0.003) and lower total cholesterol of -0.21 mmol/L (95% CI -0.42, 0.00, P = 0.05) than 195 
those in the 10 μg/day group (Supplemental Table 1). After adjustment for sex, age, Tanner 196 
stage, baseline serum 25(OH)D and BMIz, these group differences were no longer apparent 197 
(P = 0.27 and P = 0.30 respectively) and no other between-group differences were observed 198 
(Supplemental Table 2). Furthermore, linear regression analyses of changes in serum 199 
25(OH)D and in the cardiometabolic risk markers showed no dose-response effects (data not 200 
shown, all P > 0.05). 201 
 202 
Discussion 203 
There has been increased interest over recent years in the potential role of vitamin D in 204 
cardiometabolic health and CVD risk. In this sample of healthy, primarily normal weight, 205 
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white 14-18 year-old adolescents, serum 25(OH)D was inversely associated with BMIz and 206 
waist circumference after adjusting for potential confounders. However daily vitamin D3 207 
supplementation for 20 weeks at doses of 10 and 20 μg, which are in line with and cover the 208 
range of current recommendations (35, 36), had no effect on any of the cardiometabolic risk 209 
markers measured. 210 
 211 
Several studies have demonstrated negative associations between circulating 25(OH)D 212 
concentrations and measures of adiposity. Consistent with the findings of the present study, 213 
circulating 25(OH)D concentrations were associated inversely with BMI in 17 year-old 214 
Australian adolescents (37) and 12-18 year-old Korean adolescents (38), and with waist 215 
circumference in Korean and US adolescents in the respective National Health and Nutrition 216 
Examination surveys (38, 39). Due to its lipophilic nature, sequestering of vitamin D in 217 
adipose tissue, thereby reducing bioavailability, is a plausible mechanism for these 218 
associations (40). Modest weight loss in obese children and adults has been linked with an 219 
increase in 25(OH)D concentrations (41, 42). It has also been reported that obese participants 220 
with a BMI > 30 kg/m2 demonstrated a lower rise in serum 25(OH)D concentrations in 221 
response to increased oral vitamin D intake and ultra-violet B exposure than those with a BMI 222 
< 25 kg/m2, suggesting reduced bioavailability of vitamin D (40). While deposition of vitamin 223 
D in body fat is one suggested mechanism for these negative associations, reduced sun 224 
exposure due to limited mobility or avoidance of outdoor physical activity among those who 225 
are overweight/obese may also contribute (43). In contrast to the current study, others have 226 
reported circulating 25(OH)D to be inversely associated with systolic blood pressure (39, 44), 227 
glucose (44) and total and LDL cholesterol (45, 46) and positively associated with HDL 228 
cholesterol (39, 47). A systematic review of 35 observational studies and clinical trials 229 
concluded that there was no consistent association between 25(OH)D and lipid and glucose 230 
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concentrations in children and adolescents < 18 years, and that systolic blood pressure was 231 
inversely associated with 25(OH)D in cross-sectional studies, but not in prospective cohort 232 
studies (22). Additionally it was found that there was insufficient evidence to draw any 233 
conclusions on the effect of vitamin D supplementation on cardiometabolic health in children 234 
and adolescents. 235 
 236 
Findings from the limited number of vitamin D clinical and randomized controlled trials on 237 
cardiometabolic markers in adolescents have been inconsistent and inconclusive. Vitamin D 238 
at doses ranging from 10-100 μg/day for between 12 weeks and 6 months have previously 239 
demonstrated no effect on fasting glucose (24, 25), insulin (25), triglycerides or total, LDL or 240 
HDL cholesterol concentrations (25, 26). However these studies have largely been conducted 241 
in small samples (n < 60) of obese adolescents of mixed ethnic groups, at latitudes < 45°N 242 
during seasons when sun exposure will influence cutaneous synthesis of vitamin D. A larger 243 
winter-time trial of 323 primarily normal weight adolescents also found no effect of vitamin 244 
D supplementation at 10, 25, 50 and 100 μg/day for 12 weeks on fasting glucose, insulin or 245 
markers of insulin resistance (27). The mean baseline 25(OH)D concentrations of adolescents 246 
in these trials ranged from 49-70 nmol/L. Based on the recommendations of the Institute of 247 
Medicine, current consensus concedes that a 25(OH)D concentration of > 50 nmol/L is 248 
indicative of vitamin D adequacy, based on skeletal outcomes (35). Although a 25(OH)D 249 
adequacy threshold for non-skeletal outcomes has yet to be defined, it has been suggested that 250 
in order to demonstrate beneficial effects of vitamin D supplementation on non-skeletal health 251 
outcomes, including markers of CVD risk, trials should include only individuals with baseline 252 
circulating 25(OH)D concentration < 50 nmol/L (48). Daily vitamin D3 supplementation of 50 253 
μg for 16 weeks improved arterial stiffness in 18 black African American adolescents with 254 
baseline serum 25(OH)D concentrations of 33 nmol/L, although there was no effect on 255 
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systolic or diastolic blood pressure (23). In a small sample of 14 obese adolescent females 256 
with serum 25(OH)D concentrations < 50 nmol/L treated with 1,250 μg vitamin D2 once a 257 
week for 8 weeks, a tendency towards improvement in fasting glucose was seen, from 4.9 258 
mmol/L to 4.7 mmol/L (P = 0.05) (49). However, the clinical significance of a change of this 259 
magnitude is yet to be determined. Daily 25 μg vitamin D supplementation for one month 260 
increased HDL cholesterol by 0.03 mmol/L in 10-14 year-old Iranian adolescents (50). In the 261 
present study in the baseline outcome adjusted analyses, adolescents receiving 10 μg/day 262 
vitamin D3 had higher HDL and total cholesterol than those receiving 20 μg/day. This was 263 
most likely a chance finding and this did not remain significant in the fully adjusted analyses. 264 
HDL particle sub-class has been suggested as a biological pathway for the cardio protective 265 
effects seen in epidemiological studies in adults. Specifically, the large HDL particle sub-266 
class has been found to have a stronger association with circulating 25(OH)D than total HDL 267 
cholesterol (51). Vitamin D may therefore have a role in promoting the formation of large 268 
HDL particles that carry cholesterol away from atherosclerotic plaque, in an important 269 
atheroprotective process known as reverse cholesterol transport (51). However, these 270 
observations need to be confirmed in intervention trials.  271 
 272 
Due to the increasing prevalence and clustering of cardiometabolic risk factors among 273 
adolescents (18, 52), new strategies for early prevention are required. Whether vitamin D 274 
should be considered in these preventative measures remains the subject of much debate. 275 
Moreover, uncertainty remains as to the dose and duration of vitamin D supplementation 276 
needed to achieve a target 25(OH)D threshold in order to exert potential beneficial effects on 277 
cardiometabolic health. The Scientific Advisory Committee on Nutrition and Institute of 278 
Medicine recommend vitamin D dietary reference values of 10 and 15 µg/day for the UK and 279 
US population respectively based on skeletal health outcomes only, due to the respective 280 
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committees noting that a lack of consistent experimental data from randomized controlled 281 
trials could not be causally linked to non-skeletal health outcomes including CVD and 282 
hypertension (35, 36). It may well be that vitamin D intakes only above the current dietary 283 
reference values have an effect on cardiometabolic health. That current vitamin D intakes 284 
from food sources in the UK, where there is limited voluntary fortification of foods with 285 
vitamin D, are around 2-4 µg/day (53), suggests the need for targeted public health strategies 286 
to increase dietary vitamin D intakes (for review see (54)). Future randomized trials should 287 
address these challenges and consider targeting adolescents with inadequate baseline 288 
25(OH)D concentrations (< 50 nmol/L). 289 
 290 
The double-blind, placebo-controlled randomized design of this study is a major strength. The 291 
study was conducted during the winter-time at 51°N to ensure minimal UVB exposure, there 292 
was a low drop out rate (< 5%) and compliance was high. However the sample size of the 293 
study was based on serum 25(OH)D and therefore this study may have lacked power to detect 294 
small changes in the cardiometabolic markers measured. This study was conducted in healthy, 295 
primarily normal weight, white adolescents and so cannot be generalized to the wider 296 
adolescent population.  297 
 298 
In conclusion, vitamin D3 supplementation at the currently recommended dietary intakes 299 
increased winter-time serum 25(OH)D concentrations but had no effect on markers of 300 
cardiometabolic risk in healthy 14-18 year-old white adolescents.301 
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Figure Legends 
Figure 1 CONSORT flow diagram of participant enrollment, randomization and analysis to 
study intervention groups.  
CONSORT, Consolidated Standards of Reporting Trials.
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Tables 
Table 1 Baseline characteristics of participants by intervention group1  
 0 μg/day vitamin D3 10 μg/day vitamin D3 20 μg/day vitamin D3 
n 39 35 36 
Male, n (%) 16 (41) 15 (43) 16 (44) 
Age, y 15.9 ± 1.4 16.0 ± 1.4 15.9 ± 1.5 
Tanner stage, n (%)    
     III 2 (5) 2 (6) 5 (15) 
     IV 22 (56) 15 (45) 13 (40) 
     V 15 (39) 16 (49) 15 (45) 
Height, m 1.70 ± 0.09 1.69 ± 0.08 1.69 ± 0.08 
Body weight, kg 62.6 ± 15.1 61.5 ± 10.2 60.0 ± 13.2 
Weight status, n (%)2    
     Normal weight 31 (79) 28 (80) 30 (84) 
     Overweight 5 (13) 5 (14) 3 (8) 
     Obese 3 (8) 2 (6) 3 (8) 
Physical activity, mins/d3 42 (29, 48) 31 (22, 46) 42 (22, 48) 
Dietary vitamin D, μg/d 4.0 ± 2.4 4.2 ± 2.7 3.9 ± 2.1 
Dietary calcium, mg/d 909 ± 467 938 ± 492 1048 ± 609 
Serum 25(OH)D, nmol/L 46.8 ± 11.4 49.2 ± 12.0 51.7 ± 13.4 
1
 Values are mean ± SD, median (IQR) or n (%), n = 110. 
2
 Based on BMI-for-age percentiles: ≥ 2nd - < 85th normal weight; ≥ 85th - < 95th overweight; ≥ 
95th obese. Calculated using the WHO AnthroPlus software (31). 
3
 Based on frequency and duration of activity. 
25(OH)D, 25-hydroxyvitamin D.
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Table 2 Baseline associations between serum 25(OH)D and cardiometabolic risk markers in 
14-18 year-old adolescents1 
 Unadjusted Adjusted2 
 
β 95% CIs P value β 95% CIs P value 
BMI-for-age z-score3 -0.40 -6.10, -0.17 0.001 -0.44 -0.67, -0.22 < 0.001 
Waist circumference (cm) -0.04 -0.07, -0.02 0.001 -0.04 -0.07, -0.02 0.002 
Systolic blood pressure (mmHg) -0.01 -0.03, 0.03 0.94 0.01 -0.02, 0.04 0.48 
Diastolic blood pressure (mmHg) -0.01 -0.04, 0.03 0.69 0.00 -0.04, 0.03 0.88 
Plasma triglycerides (mmol/L) -0.01 -0.01, 0.00 0.008 0.00 -0.01, 0.01 0.33 
Plasma total cholesterol (mmol/L) 0.01 -0.01, 0.01 0.78 0.00 -0.01, 0.01 0.58 
Plasma HDL cholesterol (mmol/L) 0.01 -0.01, 0.04 0.27 0.00 -0.03, 0.03 0.90 
Plasma LDL cholesterol (mmol/L) 0.01 -0.01, 0.02 0.40 0.01 -0.01, 0.02 0.38 
Plasma total:HDL cholesterol -0.18 -0.58, 0.23 0.40 0.05 -0.33, 0.44 0.78 
Plasma glucose (mmol/L) -0.03 -0.06, 0.00 0.065 -0.03 -0.06, 0.01 0.10 
1
 β coefficients represent change in the cardiometabolic risk marker per 10 nmol/L increase in 
serum 25(OH)D evaluated in linear regression models, n = 110. Waist circumference and 
plasma triglycerides were log transformed before analysis and presented estimates back 
transformed. 
2
 All cardiometabolic risk markers were adjusted for sex, age, Tanner stage and physical 
activity. Systolic and diastolic blood pressure and plasma lipids and glucose were additionally 
adjusted for BMI-for-age z-score. 
3
 Calculated using the WHO AnthroPlus software (31). 
HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
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Table 3 Cardiometabolic markers at baseline and endpoint after 20 weeks of vitamin D3 
supplementation in 14-18 year-old adolescents1 
 Intervention group P value2 
 
0 µg/day 
vitamin D3  
(n = 39) 
10 µg/day 
vitamin D3 
(n = 35) 
20 µg/day 
vitamin D3 
(n = 36) 
10 vs. 0 
μg/day 
20 vs. 0 
μg/day 
20 vs. 10 
μg/day 
BMI-for-age z-scores3       
     Baseline 0.16 ± 1.03 0.12 ± 0.97 0.03 ± 1.06    
     Endpoint 0.07 ± 1.03 -0.02 ± 1.00 -0.01 ± 1.08 0.33 0.49 0.11 
Waist circumference (cm)4       
     Baseline 72.9 (69.6, 80.1) 73.4 (71.4, 84.7) 74.6 (69.9, 81.3)    
     Endpoint 73.6 (70.0, 80.8) 73.7 (68.8, 78.8) 73.1 (69.6, 80.6) 0.32 0.55 0.69 
Systolic blood pressure (mmHg)       
     Baseline 121 ± 10 124 ± 13 122 ± 10    
     Endpoint 123 ± 14 123 ± 11 121 ± 8 0.40 0.24 0.73 
Diastolic blood pressure (mmHg)       
     Baseline 67 ± 8 69 ± 10 67 ± 7    
     Endpoint 68 ± 10 71 ± 11 67 ± 6 0.46 0.54 0.18 
Plasma triglycerides (mmol/L)4       
     Baseline 0.9 (0.6, 1.3) 0.9 (0.7, 1.1) 0.8 (0.7, 1.1)    
     Endpoint 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.8 (0.6, 1.0) 0.46 0.78 0.64 
Plasma total cholesterol (mmol/L)       
     Baseline 4.0 ± 0.6 3.9 ± 0.7 4.0 ± 0.8    
     Endpoint 4.0 ± 0.7 4.1 ± 0.8 3.9 ± 0.8 0.52 0.18 0.05 
Plasma HDL cholesterol (mmol/L)       
     Baseline 1.3 ± 0.2 1.3 ± 0.3 1.4 ± 0.2    
     Endpoint 1.4 ± 0.3 1.5 ± 0.3 1.4 ± 0.3 0.20 0.07 0.003 
Plasma LDL cholesterol (mmol/L)       
     Baseline 2.2 ± 0.5 2.2 ± 0.6 2.1 ± 0.7    
     Endpoint 2.2 ± 0.6 2.2 ± 0.6 2.1 ± 0.7 0.72 0.29 0.49 
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1
 Baseline and endpoint values are unadjusted mean ± SD or median (IQR). 
2
 P values from linear regression models adjusted for baseline value of the outcome, n = 110-102. 
3
 Calculated using the WHO AnthroPlus software (31). 
4
 Waist circumference and plasma triglycerides were log transformed before analysis and presented 
estimates back transformed. 
HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
Plasma total:HDL cholesterol 
      
     Baseline 3.0 ± 0.6 3.0 ± 0.6 2.8 ± 0.6    
     Endpoint 3.0 ± 0.7 2.8 ± 0.5 2.9 ± 0.7 0.33 0.40 0.08 
Plasma glucose (mmol/L) 
      
     Baseline 5.0 ± 0.4 5.0 ± 0.4 5.1 ± 0.4    
     Endpoint 5.2 ± 0.6 5.3 ± 0.7 5.2 ± 0.6 0.46 0.96 0.44 
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10 µg/day 
Allocated and 
received 
intervention  
(n = 35) 
20 µg/day 
Allocated and 
received 
intervention  
(n = 36) 
Randomized (n = 110) 
Completed  
(n = 33) 
Analyzed  
(n = 32) 
Exclusion 
reasons: 
Outlier (n = 1) 
 
Completed  
(n = 33) 
Analyzed  
(n = 32) 
Exclusion 
reasons: 
Breach of 
protocol (n = 1) 
 
Discontinued 
intervention: 
Unwilling to 
comply (n = 2) 
 
Discontinued 
intervention: 
Unwilling to 
comply (n = 2) 
Illness (n = 1)    
Discontinued 
intervention  
(n = 0) 
 
Placebo 
Allocated and 
received 
intervention  
(n = 39) 
 
Completed  
(n = 39) 
Analyzed  
(n = 38) 
Exclusion 
reasons:  
Breach of 
protocol (n = 2) 
 
Allocation 
Enrollment 
Follow-up 
Assessed for eligibility  
(n = 132) 
Excluded: 
Not meeting inclusion         
criteria (n = 17) 
Declined to participate (n = 5) 
 
Analysis 
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